首页> 外国专利> THE PRESENT RESEARCH WORK WAS CARRIED OUT TO DEVELOP A BI-LAYER TABLET OF TOLBUTAMIDE HCL AS EXTENDED RELEASE LAYER AND ACARBOSE AS IMMEDIATE RELEASE LAYER FROM THEIR RESPECTIVE SOLID DISPERSIONS.

THE PRESENT RESEARCH WORK WAS CARRIED OUT TO DEVELOP A BI-LAYER TABLET OF TOLBUTAMIDE HCL AS EXTENDED RELEASE LAYER AND ACARBOSE AS IMMEDIATE RELEASE LAYER FROM THEIR RESPECTIVE SOLID DISPERSIONS.

机译:目前正在进行的研究工作是从其各自的固体分散体中开发出厚层的甲苯胺盐酸盐盐酸盐,以作为扩展的释放层,而碳糖作为其近期的释放层。

摘要

The present investigation studied a novel Bilayer tablet having Extended Release system of Tolbutamide with Eudragit RS 100 and RL 100 and Immediate Release system of Acarbose with PVP K30 and PEG 6000 in different ratios using solvent evaporation and cogrinding techniques. SDs was characterized by Fourier-transformed Infrared Spectroscopy (FT-IR), Differential Scanning Calorimetry (DSC), Powder X-Ray Diffractometry (XRD), Scanning Electron Microscopy (SEM) as well as by content uniformity, in-vitro dissolution studies and release kinetics. Selected SD system was subjected to Bilayer tablet preparation by direct compression. Compressed tablets were evaluated for drug content, weight variation, friability, hardness, thickness, and in-vitro dissolution studies. The progressive disappearance of IR, X-Ray and thermotropic drug signals in SDs and physical mixtures were related to increasing amount of polymers. SEM studies suggested the homogenous dispersion of drug in polymers. FT-IR studies confirmed the formation of hydrogen bonding between drug and polymer. All tablet formulations showed compliance with pharmacopoeial standards and were of acceptable quality with regard to hardness, friability and tensile strength. In-vitro dissolution studies were carried out in a USP apparatus II. The formulations gave an initial burst effect to provide the loading dose of the drug followed by extended release for 12 hrs. In-vitro dissolution kinetics followed the Higuchi model via a non-Fickian diffusion controlled release mechanism after the initial burst release. Stability studies conducted for optimized formulation did not show any change in physical properties, drug content, and in-vitro drug release. The present study concluded that Bilayer tablets of Tolbutamide and Acarbose as an alternative to the conventional dosage form.
机译:本研究使用溶剂蒸发和共研磨技术研究了一种新型双层片剂,该片剂具有甲苯磺丁脲的缓释系统和Eudragit RS 100和RL 100的缓释系统,以及阿卡波糖的速释系统和PVP K30和PEG 6000的不同比例。 SD的特征在于傅立叶变换红外光谱(FT-IR),差示扫描量热法(DSC),粉末X射线衍射法(XRD),扫描电子显微镜(SEM)以及含量均匀性,体外溶出度研究和释放动力学。通过直接压制对选定的SD系统进行双层片剂制备。评价压制片剂的药物含量,重量变化,易碎性,硬度,厚度和体外溶出度研究。 SD,物理混合物中IR,X射线和热致药物信号的逐渐消失与聚合物量的增加有关。 SEM研究表明药物在聚合物中的均匀分散。 FT-IR研究证实了药物与聚合物之间氢键的形成。所有片剂的配方均符合药典标准,并且在硬度,脆性和拉伸强度方面均处于可接受的质量。体外溶出度研究是在USP装置II中进行的。该制剂产生了最初的爆发作用,以提供药物的负载剂量,随后延长释放12小时。在初始爆发释放后,通过非菲克扩散控制释放机制遵循Higuchi模型进行体外溶出动力学。为优化配方而进行的稳定性研究未显示物理性质,药物含量和体外药物释放的任何变化。本研究得出的结论是,甲苯磺丁胺和阿卡波糖的双层片剂可替代常规剂型。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号